Lancet Oncol:伏立诺他可治疗晚期恶性胸膜间皮瘤吗?

2015-03-26 崔倩译 MedSci原创

背景 伏立诺他是一种组蛋白脱乙酰酶抑制剂,它可以改变基因表达和蛋白质的活性。在对报道的恶性胸膜间皮瘤的患者在伏立诺他的第一阶段研究治疗的临床获益的基础上,我们设计了这个3期试验,研究伏立诺他是否可以作为二线或三线治疗来改善患者的总生存期。 方法 这项双盲,随机,安慰剂对照试验在90个国际中心已完成。晚期恶性胸膜间皮瘤患者和经过一个或两个以前的系统性方案可衡量的疾病进展均符合要求。对KPS评分、

背景 伏立诺他是一种组蛋白脱乙酰酶抑制剂,它可以改变基因表达和蛋白质的活性。在对报道的恶性胸膜间皮瘤的患者在伏立诺他的第一阶段研究治疗的临床获益的基础上,我们设计了这个3期试验,研究伏立诺他是否可以作为二线或三线治疗来改善患者的总生存期。

方法 这项双盲,随机,安慰剂对照试验在90个国际中心已完成。晚期恶性胸膜间皮瘤患者和经过一个或两个以前的系统性方案可衡量的疾病进展均符合要求。对KPS评分、组织学和化疗方案的数量进行分层,患者通过使用交互式语音响应系统被随机分配(1:1)为伏立诺他组或安慰剂组。患者在第1,2,3,8,9,10,15,16,17天,21天的周期接受口服伏立诺他300毫克(或匹配的安慰剂),每日两次。主要终点是总生存和安全性以及伏立诺他的耐受性。主要疗效比较是在意向治疗人群中进行,安全性和耐受性在治疗的群体中进行了评估。 

发现 从2005年7月12日到2011年2月14日,661例患者随机分配接受伏立诺他(n =329)或安慰剂(n=332),并包含在意向处理分析。对伏立诺他中位总生存期为30•7个周(95%CI 26•7-36•1),安慰剂组为27•1个周(23•1-31•9),(危险比0•98,95%CI 0•83-1•17,p =0•86)。伏立诺他治疗的患者最常见的3级或更坏的不良事件是疲劳或不适(伏立诺他组为51例[16%],安慰剂组为25例[8%])和呼吸困难(35[11%]和45 [14%])。

说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。

原始出处

Dr Lee M Krug, MD, Prof Hedy L Kindler, MD, Hilary Calvert, MD.et.al.Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.Lancet Oncol. 2015 Mar 19.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828039, encodeId=6f72182803918, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 12 20:53:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864629, encodeId=bf93186462908, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat May 30 15:53:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666246, encodeId=09401666246be, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Sat Jun 06 06:53:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24669, encodeId=303724669c7, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:22:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579783, encodeId=42e915e9783e6, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 28 04:53:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18920, encodeId=325b1892053, content=说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。 意味着表观遗传治疗的第一个失败, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 26 20:25:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2015-12-12 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828039, encodeId=6f72182803918, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 12 20:53:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864629, encodeId=bf93186462908, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat May 30 15:53:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666246, encodeId=09401666246be, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Sat Jun 06 06:53:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24669, encodeId=303724669c7, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:22:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579783, encodeId=42e915e9783e6, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 28 04:53:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18920, encodeId=325b1892053, content=说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。 意味着表观遗传治疗的第一个失败, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 26 20:25:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2015-05-30 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828039, encodeId=6f72182803918, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 12 20:53:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864629, encodeId=bf93186462908, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat May 30 15:53:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666246, encodeId=09401666246be, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Sat Jun 06 06:53:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24669, encodeId=303724669c7, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:22:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579783, encodeId=42e915e9783e6, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 28 04:53:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18920, encodeId=325b1892053, content=说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。 意味着表观遗传治疗的第一个失败, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 26 20:25:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2015-06-06 lifestar
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828039, encodeId=6f72182803918, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 12 20:53:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864629, encodeId=bf93186462908, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat May 30 15:53:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666246, encodeId=09401666246be, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Sat Jun 06 06:53:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24669, encodeId=303724669c7, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:22:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579783, encodeId=42e915e9783e6, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 28 04:53:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18920, encodeId=325b1892053, content=说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。 意味着表观遗传治疗的第一个失败, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 26 20:25:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2015-05-24 ljjj1053

    不错,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1828039, encodeId=6f72182803918, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 12 20:53:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864629, encodeId=bf93186462908, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat May 30 15:53:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666246, encodeId=09401666246be, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Sat Jun 06 06:53:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24669, encodeId=303724669c7, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:22:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579783, encodeId=42e915e9783e6, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 28 04:53:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18920, encodeId=325b1892053, content=说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。 意味着表观遗传治疗的第一个失败, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 26 20:25:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1828039, encodeId=6f72182803918, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 12 20:53:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864629, encodeId=bf93186462908, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat May 30 15:53:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666246, encodeId=09401666246be, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Sat Jun 06 06:53:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24669, encodeId=303724669c7, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:22:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579783, encodeId=42e915e9783e6, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Sat Mar 28 04:53:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18920, encodeId=325b1892053, content=说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。 意味着表观遗传治疗的第一个失败, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 26 20:25:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2015-03-26 lovetcm

    说明 在这项随机试验中,伏立诺他作为一个二线或三线治疗并未改善整体生存期,所以不能推荐作为用于治疗晚期恶性胸膜间皮瘤的疗法。 意味着表观遗传治疗的第一个失败

    0